This new mental health technology could be a game-changer

Follow Me on X (new)!

*Sponsored by Psycheceutical Bioscience

Hey Boardroom, how you doing?

In honor of Veteran’s Day this past weekend, my wife and I watched one of our favorite movies based on a true story – Hacksaw Ridge.  My wife doesn't usually like war movies, but she loves this one, especially the part, “Help me get one more, Lord.”

What a true hero and a humble man.

But it had me thinking about the soldiers that survived, including Desmond, and the trauma they must have to deal with all their lives. So it was interesting when my newest partner in the Boardroom, Psycheceutical Bioscience, contacted me about potentially life-changing research the company is doing to help people suffering from PTSD and other mental disorders (a market of 300 million plus people).

The company recently released THIS ARTICLE about its NeuroDirect™ topical ketamine formula for the treatment of PTSD that targets NMDA receptors – without entering the bloodstream. 

According to NeuroDirect’s developing physician, Dr. Aung-Din, “The theory is that this precise, nonsystemic action allows ketamine to speak directly to brain regions involved with PTSD symptoms.” If all aligns, NeuroDirect creams could rein over pills and injections as one of the most prescribed technologies for targeted healing.

Initial research is ongoing, but early observational data has been positive.  For example, one patient diagnosed with PTSD, heavy metal poisoning, anxiety disorder, and fibromyalgia felt ‘chi’ and ‘at peace,’ as well as a drastic mood improvement after using the cream. You can read about all their studies and initial findings HERE.  

It has everybody extremely excited…

Another person extremely excited about Psycheceutical’s potential is one of the original “Sharks” from Shark Tank , Kevin Harrington. A recent Benzinga Article reinforces the proposition that psychedelics will be the future of mental health care:

Kevin Harrington thinks safe psychedelic medicines without the ‘trip’ are the future of mental health care, and has put his support behind Psycheceutical.

So how can people like you or me play a part in helping move this ball forward?

By doing a deep dive into the company and seeing if it is worth an investment.  

Psycheceutical (trading on the OTC as BWVI) is conducting a Reg CF campaign through Wefunder to further its research and development, including trials of its ketamine topical for the treatment of PTSD.

You might be asking, “Why is the company raising funds via a CF if it’s already public?”

CEO Chad Harman explains in our recent Boardroom interview that they’re doing this to give a wider base of investors the opportunity to invest, as increasing the number of investors will allow the company to uplist to a bigger exchange. 

In a nutshell, by investing through Wefunder, new investors gain more favorable terms and a better entry price than simply going directly to the exchange. 

Please take some time to dig into the details as these types of partnerships could have far-reaching implications. Two good places to review are the company’s fundraising page and their investor presentation.  

That’s it for now, thanks for reading!

*Sponsored content. Like all investments, this investment involves substantial risk. Please see full disclosures below.

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions